You are here

  • Home
  • Archive
  • Volume 2, Issue 1
  • Serum α-hydroxybutyrate (α-HB) predicts elevated 1 h glucose levels and early-phase β-cell dysfunction during OGTT

Article info

Article menu
XML
Epidemiology/Health service research
Serum α-hydroxybutyrate (α-HB) predicts elevated 1 h glucose levels and early-phase β-cell dysfunction during OGTT

Authors

  1. Correspondence to Dr Stephen A Varvel; svarvel{at}hdlabinc.com
View Full Text

Citation

Varvel SA, Pottala JV, Thiselton DL, et al
Serum α-hydroxybutyrate (α-HB) predicts elevated 1 h glucose levels and early-phase β-cell dysfunction during OGTT
BMJ Open Diabetes Research and Care 2014;2:e000038. doi: 10.1136/bmjdrc-2014-000038

Publication history

  • Received May 1, 2014
  • Revised August 22, 2014
  • Accepted September 1, 2014
  • First published September 24, 2014.
Online issue publication 
May 28, 2020

  • Supplementary Data

    This web only file has been produced by the BMJ Publishing Group from an electronic file supplied by the author(s) and has not been edited for content.

    Files in this Data Supplement:

Request permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

Copyright information

Published by the BMJ Publishing Group Limited. For permission to use (where not already granted under a licence) please go to http://group.bmj.com/group/rights-licensing/permissions This is an Open Access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/